A randomized clinical trial tested whether Mindfulness-Based Cognitive Therapy to Prevent Suicide (MBCT-S) improves attentional control, an objective marker of suicide attempt, in 135 high suicide risk Veterans. Seventy Veterans received MBCT-S plus enhanced treatment as usual (eTAU), and 65 received eTAU only. Computerized Stroop and emotion Stroop tasks were administered three times over six months. Veterans receiving MBCT-S showed a more favorable trajectory of attentional control over time, with improved combat-stress interference scores. Interference processing time for negative affective words deteriorated over time among Veterans receiving eTAU only. The authors suggest MBCT-S may effectively target attentional control in high suicide risk Veterans.
Mindfulness-Oriented Recovery Enhancement (MORE) added to methadone maintenance treatment (MMT) reduced illicit drug use, craving, pain, physical and emotional limitations, depression, and anxiety, while increasing well-being, vitality, and social functioning through 16-week follow-up compared to MMT alone. In this randomized trial of 30 individuals in MMT, those receiving eight weekly two-hour MORE groups plus treatment as usual showed significantly better outcomes than those receiving only treatment as usual. The authors conclude that MORE could be an effective adjunct to MMT and that larger trials are warranted.
Mindfulness-Oriented Recovery Enhancement (MORE) improved opioid craving, pain unpleasantness, stress, and positive affect more than treatment as usual among individuals with opioid use disorder and chronic pain receiving methadone maintenance therapy. Participants in MORE reported nearly 1.3 times greater self-control over craving. Positive affect was associated with reduced craving, and this link was significantly stronger for those in MORE. The findings suggest MORE may serve as a useful non-pharmacological adjunct for this population.